Oral contraceptives and the periodontium

被引:18
作者
Preshaw, Philip M.
机构
关键词
HUMAN PROGESTERONE-RECEPTOR; SEX STEROID-HORMONES; ESTROGEN-RECEPTORS; VENOUS THROMBOEMBOLISM; CYCLE CONTROL; MU-G; RISK; WOMEN; DISEASE; HEALTH;
D O I
10.1111/j.1600-0757.2011.00399.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Oral contraceptives are a safe and effective means of contraception for millions of women worldwide. The first formulations of these drugs contained much higher doses of estrogens and progestins than those available today, and these were associated with an unacceptably high rate of unwanted effects including serious cardiovascular events. In addition, a number of case reports and clinical studies suggested that use of the first generation oral contraceptives was also associated with an increased risk for gingival and/or periodontal disease. Unfortunately, many of these early studies suffered from significant methodological flaws which throw their findings into question. Nonetheless, these studies provided the basis for a perception among the dental profession that oral contraceptives increase the risk for gingivitis and/or periodontitis. Realisation that the adverse events profile of oral contraceptives was dose dependant led to the development of the modern low dose formulations that are in use today. There have been far fewer studies to investigate whether modern oral contraceptives have any impact on the periodontium compared to studies of the early contraceptive formulations, but the quality of the more recent research is undoubtedly better. Following extensive review of the relevant literature and consideration of the historical perspective, the best available evidence strongly supports that oral contraceptives no longer place users at any increased risk for gingivitis or periodontitis. Oral contraceptives should not be viewed as a risk factor for gingival or periodontal disease.
引用
收藏
页码:125 / 159
页数:35
相关论文
共 156 条
[1]   COMPARATIVE PROFILES OF RELIABILITY, CYCLE CONTROL AND SIDE-EFFECTS OF 2 OR AL CONTRACEPTIVE FORMULATIONS CONTAINING 150 MU-G DESOGESTREL AND EITHER 30 MU-G OR 20 MU-G ETHINYL ESTRADIOL [J].
AKERLUND, M ;
RODE, A ;
WESTERGAARD, J .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (09) :832-838
[2]  
Amar S, 1994, Periodontol 2000, V6, P79, DOI 10.1111/j.1600-0757.1994.tb00028.x
[3]  
[Anonymous], 1995, LANCET, V346, P1569
[4]   A COMPARISON OF A NEW GRADUATED ESTROGEN FORMULATION WITH 3 CONSTANT-DOSED ORAL-CONTRACEPTIVES [J].
APPEL, TB ;
KAMBI, AA ;
BIRDSALL, C ;
CHRISTENSON, DA ;
CLARK, DO ;
DEKONING, JR ;
DREISBACH, LA ;
FROST, JF ;
GUSTIN, AE ;
HALIKIS, M ;
HART, TJ ;
HLAYACKEK, JH ;
HOFFPAUIR, NS ;
HUBBELL, W ;
KANGAYAPPAN, S ;
KUK, DS ;
LACKEY, OM ;
LESKO, CA ;
LEVISION, J ;
LEVITAN, DB ;
LUCCA, PA ;
MAXYMIV, GW ;
MCWHORTER, JR ;
MELTON, RW ;
MINARD, WD ;
POLICH, JJ ;
RIES, T ;
STEWART, SK ;
THORNTON, TL ;
WHITE, WR .
CONTRACEPTION, 1987, 35 (06) :523-532
[5]  
Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1
[6]  
Bancroft K, 1990, ANN PERIODONTOL, V6, P33
[7]   A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles [J].
Bannemerschult, R ;
Hanker, JP ;
Wünsch, C ;
Fox, P ;
Albring, M ;
Brill, K .
CONTRACEPTION, 1997, 56 (05) :285-290
[8]   ORAL CONTRACEPTIVES AND DENTAL CARE [J].
BARBER, DN .
BRITISH MEDICAL JOURNAL, 1967, 4 (5576) :417-&
[9]  
Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1
[10]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596